Genelux (GNLX) Stock Price, News & Analysis

Company Overview

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Key Stats

• Today's Range: $2.40 to $2.59
• 50-Day Range: $1.62 to $2.83
• 52-Week Range: $1.60 to $26.07
• Volume: 118,692 shs
• Average Volume: 184,271 shs
• Market Capitalization: $86.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.33
• Consensus Rating: Buy

Genelux Stock Analysis - MarketRank™

Genelux scored higher than 48% of companies evaluated by MarketBeat, and ranked 622nd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Genelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genelux has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Genelux are expected to decrease in the coming year, from ($0.90) to ($0.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genelux is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genelux is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Genelux has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.07% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Genelux has recently decreased by 1.74%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genelux does not currently pay a dividend.

Dividend Growth

Genelux does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.07% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Genelux has recently decreased by 1.74%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Genelux has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

Search Interest

Only 3 people have searched for GNLX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $736,831.00 in company stock.

Percentage Held by Insiders

Only 9.30% of the stock of Genelux is held by insiders.

Percentage Held by Institutions

Only 37.33% of the stock of Genelux is held by institutions.

GNLX Stock Analysis - Frequently Asked Questions

How have GNLX shares performed this year?

Genelux's stock was trading at $14.01 at the beginning of the year. Since then, GNLX shares have decreased by 82.0% and is now trading at $2.52.
View the best growth stocks for 2024 here.

How were Genelux's earnings last quarter?

Genelux Co. (NASDAQ:GNLX) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03.

When did Genelux IPO?

Genelux (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/05/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNLX
• CUSIP: N/A
• CIK: 1231457
• Web: www.genelux.com
• Phone: 805-267-9889
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.33
• High Stock Price Target: $32.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +786.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-28,300,000.00
• Net Margins: N/A
• Pretax Margin: -331,724.97%
• Return on Equity: -110.28%
• Return on Assets: -80.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.01
• Quick Ratio: 6.01

Sales & Book Value

• Annual Sales: $8,000.00
• Price / Sales: 10,820.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 3.45

Miscellaneous

• Outstanding Shares: 34,352,000
• Free Float: 31,157,000
• Market Cap: $86.57 million
• Optionable: Not Optionable
• Beta: -1.54